Hunt­ing a block­buster, Bay­er forges an $875M-plus M&A deal to ac­quire women’s health biotech

Bay­er has dropped $425 mil­lion in cash on its lat­est women’s health bet, bring­ing a UK biotech and its non-hor­mon­al menopause treat­ment in­to the fold.

KaNDy Ther­a­peu­tics had its roots in Glax­o­SmithK­line, which spun out sev­er­al neu­ro­science drugs in­to NeRRe Ther­a­peu­tics back in 2012. Five years lat­er the team cre­at­ed a new biotech to fo­cus sole­ly on NT-814 — which they con­sid­ered “one of the few true in­no­va­tions in women’s health in more than two decades.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN